Novozymes is planning to raise prices across its portfolio as a result of rising costs, the enzyme producer reports in a press release issued Friday.
”Novozymes has experienced unprecedented cost-inflation on raw materials, energy, and logistics. To recover these headwinds, substantial price increases will be implemented,” the company notes.
Up to this point, the company had refrained from passing rising costs on to customers. Now Novozymes sees no other option but to raise prices in keeping with the current inflation level at minimum in order to ensure ”continued innovation and supply robustness.”
Novozymes’ share price dips 0.1% to DKK 422.20 during morning trading at the Copenhagen stock exchange.